Systemic Antimicrobials Consumption and Expenditures in Multi-Profile Hospitals in Russian Federation and Republic of Belarus: the Results of Multicenter Pharmacoepidemiological Trial

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(4):322-341

​ Belkova Yu.А., Rachina S.A., Kozlov R.S., Mischenko V.M., Kozhuhova L.L., Abubakirova A.I., Berezhanskiy B.V., Eliseeva E.V., Zubareva N.A., Karpov I.A., Kopylova I.A., Korneva E.V., Palyutin Sh.H., Portnyagina U.S., Pribytkova O.V., Samuylo E.K.
pharmacoepidemiology systemic antimicrobials consumption expenditures
Section
Pharmacoepidemiology
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(4):322-341

Abstract

To assess systemic antimicrobials (AM) consumption and expenditures in multi-profile hospitals in different regions of Russian Federation and Republic of Belarus in 2009–2010 retrospective collection of data from hospital receipts notes was performed. AM consumption was calculated using ATC/DDD methodology and expressed in numbers of DDD/100 bed-days (DBD). Average AM consumption and expenditure rates in 2009 and 2010 were as follows: 40.2 DBD / 10.5 million rubles and 34.4 DBD / 7.8 million rubles; average cost of 1 DDD – 101 rubles and 72.8 rubles, respectively. The highest consumption rates were for antibacterials for systemic use, J01 (96% in 2009 and 96.3% in 2010), such as non-penicillin beta-lactams, J01D (41.2% and 38.3%), penicillins, J01C (28.8% and 24%) and quinolones, J01M (11.1% and 15.9%, respectively); the highest expenditure rates – for antibacterials for systemic use, J01 (97.7% in 2009 and 98.1% in 2010), such as non-penicillin betalactams, J01D (60.6% and 63.8%), penicillins, J01C (14.1% and 11.1%) and quinolones, J01M (10.5% and 10.2%, respectively). Improper AM consumption (17.7% in 2009 and 14.6% in 2010) and expenditure rates (12.6% and 8%, respectively) were unreasonably high. Study outputs can be used for budget allocation and AM distribution improvement in multi-profile hospitals as well as for development and efficacy control of local antimicrobial stewardship program.

  • 1. Armstrong G. L., Conn L.A., Pinner R.W. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281:61–6.
  • 2. Shurland S., Zhan M., Bradham D.D., et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28(3):273-9.
  • 3. Maragakis L.L., Perencevich E.N., Cosgrove S.E. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6(5):751–63.
  • 4. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2): S82–9.
  • 5. Научный отчет о результатах исследования антибиотикорезистентности бактериальных возбудителей нозокомиальных инфекций в отделениях с интенсивным использованием антибиотиков в стационарах России (РеВАНШ). НИИАХ, Смоленск, 2009.
  • 6. Дехнич А.В., Никулин А.А., Рябкова Е.Л., Кречикова О.И., Сухорукова М.В., Козлов Р.С., исследовательская группа РОСНЕТ* – Эпидемиология резистентности штаммов S. aureus, выделенных от пациентов в ОРИТ российских стационаров: результаты многоцентрового исследования. Clinical Microbiology and Antimicrobial Chemotherapy.2008; 10(4):333-44.
  • 7. Эйдельштейн М.В., Склеенова Е.Ю., Шевченко О.В. и соавт. Распространенность и молекулярная эпидемиология грамотрицательных бактерий, продуцирующих металло-β-лактамазы, в России, Беларуси и Казахстане. Клин микробиол антимикроб химиотер 2012;14(2):132-52.
  • 8. Livermore D.M. The zeitgeist of resistance. J Antimicrob Chemother 2007; 60(Suppl 1): i59–61.
  • 9. Lieberman J.M. Appropriate antibiotic use and why it is important: the challenges of bacterial resistance. Pediatr Infect Dis J 2003; 22:1143-51.
  • 10. Paterson D.L. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis 2006; 42(Suppl 2):S90-5.
  • 11. Fridkin S.K., Lawton R., Edwards J.R., et al. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002; 8: 702–7.
  • 12. Hanberger H., Arman D., Gill H., et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 2009; 35: 91–100.
  • 13. ESAC Yearbook 2009. Available from URL: www.esac. ua.ac.be/download.aspx?c=*ESAC2&n=50036&ct=500 33&e=50536.
  • 14. Паравина Е.В., Жестков А.В., Кулагин О.Л. Комплексный анализ и возможности оптимизации системной антимикробной терапии в многопрофильном стационаре. Известия Самарского научного центра РАН 2010;12(1):1865-70.
  • 15. Willemsen I., Groenhuijzen A., Bogaers D., et al. Appropriateness of antimicrobial therapy measured by repeated prevalence surveys. Antimicrob Agents Chemother 2007; 51(3):864-7.
  • 16. Available from URL: www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/
  • 17. World Health Organization. Introduction to Drug Utilization Research. 2003. Available from URL: www.whocc.no/filearchive/publications/drugutilization research.pdf
  • 18. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious diseases society of America and the Society for healthcare epidemiology of America Guidelines for developing an Institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
  • 19. Goossens H., Ferech M., Vander Stichele R., et al. Outpatient antibiotic use in Europe and association with resistance:a cross-national database study. Lancet 2005; 365:579-87.
  • 20. Saurina G., Quale J.M., Manikal V.M., et al. Antimicrobial resistance in Enterobacteriacea in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000; 45:895-8.
  • 21. Lautenbach E., Patel J.B., Bilker W.B., et al. Extended spectrum beta-lactamase-producing E. coli and K. pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
  • 22. Tacconelli E., De Angelis G., Cataldo M.A., et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008; 61:26-38.
  • 23. Fridkin S.K., Edwards J.R., Courval J.M., et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 US adult intensive care unit. Ann Intern Med 2001; 135:175-83.
  • 24. Schwaber M.J., Simhon. A., Block C., et al. Factors associated with nosocomial diarrhea and C. difficile associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000; 19:9-15.
  • 25. ESAC Yearbook 2006. Available from URL: www.esac. ua.ac.be/download.aspx?c=*ESAC2&n=50036&ct=500 33&e=50185.
  • 26. Ludlam H., Brown N., Sule O., et al. An antibiotic policy associated with reduced risk of C. difficile-associated diarrhea. Age Ageing 1999; 28:578-80.
  • 27. Zavascki A.P., Barth A.L., Gaspareto P.B., et al. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiarycare teaching hospitals. J Antimicrob Chemother 2006; 58:882-5.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared